Rising Rates of Drinking During Pregnancy Spark Concern for Child Health

Summary

After decades of decline, alcohol consumption among pregnant women in the United States has been climbing steadily over the past ten years. The increase is so significant that drinking during pregnancy is now more common than gestational diabetes. According to recent data, more than one in eight pregnant adults report having consumed alcohol in the past month.

The patterns of this consumption are particularly concerning to health researchers. Among the expectant mothers who reported drinking recently, one quarter engaged in binge drinking, which means they consumed four or more alcoholic beverages in a single sitting. Medical experts are careful to point out a major caveat: not every fetus exposed to alcohol will go on to develop birth defects or intellectual disabilities. However, the rising rates still represent a major shift in prenatal health behavior.

Why it matters.

This upward trend is alarming because prenatal alcohol exposure is the direct cause of fetal alcohol spectrum disorders, or FASDs. These conditions are a leading cause of neurodevelopmental challenges in children. While the exact national prevalence of FASDs remains difficult to definitively measure and relies primarily on localized community studies, the available numbers are striking. Estimates suggest that as many as one in 20 school-aged children might have an FASD, making it potentially more common than autism, which affects about one in 31 children.

The steady increase in prenatal drinking presents a growing challenge for public health officials and the medical system. If these trends continue, pediatricians and educators could face a rising population of children requiring specialized developmental support. This data highlights a critical need for the healthcare industry to better communicate the unique risks of prenatal alcohol exposure to expectant parents.

From the source

The story in numbers.

Pregnant adults reporting alcohol consumption in the past month: 1 in 8
Pregnant alcohol consumers who reported binge drinking in the prior month: 25%
School-aged children estimated to have a fetal alcohol spectrum disorder: 1 in 20

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

Rising Rates of Drinking During Pregnancy Spark Concern for Child Health

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.